7 terminated, 5 completed, 2 active not recruiting, 2 withdrawn. 15 Phase 2, 4 Phase 3, 1 Phase 1.
Follow TACI receptor-IgG Fc fragment fusion protein: new trials by email Literature Review of TACI receptor-IgG Fc fragment fusion protein trials Research Report on TACI receptor-IgG Fc fragment fusion protein
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Atacicept in Multiple Glomerular Diseases Atacicept - pMN, IgAN | Phase 2 | Recruiting | Vera Therapeutics, Inc. | 250 | 2025-07-07 | 2026-06-26 |
| Monthly Dosing of Atacicept in IgAN Atacicept - IgA Nephropathy (IgAN), Berger Disease | Phase 2 | Active not recruiting | Vera Therapeutics, Inc. | 90 | 2025-05-29 | 2026-04-13 |
| A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept Atacicept 150 mg - IgA Nephropathy (IgAN), Renal and Urinary Disorders | Phase 2 | Enrolling by invitation | Vera Therapeutics, Inc. | 750 | 2024-12-01 | 2026-06-22 |
| Atacicept in Subjects With IgA Nephropathy Atacicept, Placebo to match Atacicept - IgA Nephropathy, Berger Disease | Phase 3 | Active not recruiting | Vera Therapeutics, Inc. | 428 | 2023-06-29 | 2026-10-01 |
| Atacicept in Subjects With Active Lupus Nephritis (COMPASS) Atacicept, Placebo - Lupus Nephritis (LN) | Phase 3 | Withdrawn | Vera Therapeutics, Inc. | 2022-11-02 | 2025-05-23 | |
| Efficacy and Safety of Atacicept in IgA Nephropathy Placebo, Atacicept 25 mg, Atacicept 75 mg - IgA Nephropathy | Phase 2 | Terminated | EMD Serono Research & Development Institute, Inc. | 16 | 2017-01-31 | 2021-02-25 |
| Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II) Atacicept 75 mg, Atacicept 150 mg - Lupus Erythematosus, Systemic | Phase 2 | Terminated | EMD Serono | 253 | 2014-07-29 | 2019-03-21 |
| Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus Atacicept 75 milligram (mg), Atacicept 150 mg, Placebo - Lupus Erythematosus, Systemic | Phase 2 | Completed | EMD Serono | 306 | 2013-12-01 | 2018-01-02 |
| Atacicept Demonstrating Dose RESponSe Placebo, Atacicept - Systemic Lupus Erythematosus | Phase 2 | Withdrawn | EMD Serono | 2012-02-01 | 2013-08-21 | |
| Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate Mofetil Atacicept - Lupus Nephritis | Phase 1 | Terminated | EMD Serono | 1 | 2011-06-01 | 2013-10-22 |
| Atacicept in Multiple Sclerosis Extension Study, Phase II Atacicept 25 mg, Atacicept 75 mg, Atacicept 150 mg - Relapsing Multiple Sclerosis | Phase 2 | Terminated | EMD Serono | 74 | 2009-03-01 | 2017-03-20 |
| Atacicept in Subjects With Optic Neuritis Atacicept, Placebo matched to atacicept - Optic Neuritis | Phase 2 | Terminated | EMD Serono | 34 | 2008-06-01 | 2016-02-17 |
| A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS) Atacicept, Placebo matched to atacicept - Relapsing Multiple Sclerosis | Phase 2 | Terminated | EMD Serono | 255 | 2008-04-01 | 2016-05-24 |
| Atacicept in Combination With Rituximab in Subjects With Rheumatoid Arthritis (August III) Rituximab, Atacicept, Placebo matched to atacicept - Rheumatoid Arthritis | Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 27 | 2008-03-01 | 2016-12-30 |
| Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE) Atacicept 75 mg, Atacicept 150 mg, Placebo Comparator - Lupus Erythematosus, Systemic | Phase 2 / Phase 3 | Completed | EMD Serono | 461 | 2008-01-01 | 2016-03-14 |
| The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis Atacicept, Mycophenolate mofetil, Placebo - Lupus Nephritis | Phase 2 / Phase 3 | Terminated | EMD Serono | 6 | 2007-12-01 | 2016-03-23 |
| Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II) Placebo matched to atacicept, Atacicept: with loading dose, Atacicept - Rheumatoid Arthritis | Phase 2 | Completed | EMD Serono | 311 | 2007-09-01 | 2016-02-17 |
| A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I) Atacicept, Placebo matched to atacicept - Rheumatoid Arthritis | Phase 2 | Completed | EMD Serono | 256 | 2006-12-01 | 2016-02-17 |
Glomerulonephritis, IGA (5) · Lupus Erythematosus, Systemic (5) · Arthritis, Rheumatoid (3) · Lupus Nephritis (3) · Glomerulonephritis (2) · Nephritis (2) · Arthritis (1) · Autoimmune Diseases (1) · Immune System Diseases (1) · Kidney Diseases (1) · Macular dystrophy, corneal type 1 (1) · Nephrotic Syndrome (1) · Neuritis (1) · Optic Neuritis (1) · Proteinuria (1)
EMD Serono (11) · Vera Therapeutics, Inc. (5) · EMD Serono Research & Development Institute, Inc. (1) · Merck KGaA, Darmstadt, Germany (1)
United States (16) · United Kingdom (8) · Czechia (7) · Germany (7) · Spain (7) · France (5) · Russia (5) · Australia (4) · Canada (4) · Lebanon (4) · Netherlands (4) · Switzerland (4) · Argentina (3) · Belgium (3) · Bulgaria (3)
Eric Michael, MD (2) · Daniel Mikol, MD, PhD (1) · Joanne Curley (1) · Pam Winterberg (1) · Stephen Wax, MD, PhD (1) · Zeeshan Khawaja (1)
PMID 24613349, PMID 37332136, PMID 21452293, PMID 21452294, PMID 22325903, PMID 24951103, PMID 26137975, PMID 29073347, PMID 32107560, PMID 33547784, PMID 36532058, PMID 39462308, PMID 41196369, PMID 41620980
2016 (1)